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Objectives: The aim of this study was to identify, compare and evaluate regulatory
requirements for the biosimilar development and review processes in BRICS-TM (Brazil,
Russia, India, China, South Africa, Turkey, Mexico) countries with mature regulatory
systems of Australia, Canada, Singapore and Switzerland. It is hoped that this
benchmark study provides an opportunity for BRICS-TM agencies to identify the key
areas for improvement in their regulatory processes.
Materials and Methods: A semi-quantitative questionnaire was developed covering the
different criteria used in biosimilar development and registration process. Eleven regulatory
agencies from BRICS-TM and ACSS (Australia, Canada, Switzerland and Singapore)
countries were invited to take part in this study. Data processing and analysis was carried
out using descriptive statistics for quantitative data and content analysis to generate
themes for qualitative data.
Results and Discussions: Nine of the 11 regulatory agencies recruited for the study
completed the questionnaire. China and Singapore did not meet the deadline due to lack of
resources. The organisational structure of BRICS-TM agencies revealed support from
external assessors by most of these agencies in comparison with ACSS agencies. There
was absence of reliance approach and participation in harmonisation activities across
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most BRICS-TM agencies. Despite alignment over biosimilarity, the mandate for in vivo
non-clinical studies and additional local clinical studies in some of the BRICS-TM countries
illustrates a lack of effective implementation of a step-wise approach. Adopting flexible
regulatory standards in the sourcing of a RBP (Reference Biologic Product) by BRICS-TM
similar to ACSS, will facilitate cost-effective development of biosimilar products.
Conclusions: Comparative assessment of the biosimilar regulatory framework of BRICS-
TM with ACSS agencies reveals the scope for enhancing efficiency of the regulatory
approval process. To achieve this, BRICS-TM agencies should consider relying on
reference agencies for alternative review mechanisms such as abridged or verification
models, streamlined processes for providing scientific advice to developers and for waiving
local clinical studies in-lieu of advanced scientific data.
Keywords: BRICS-TM, ACSS biosimilar, regulatory agency, development, emerging markets
INTRODUCTION
Developing economies account for one-third of global growth in
drug demand, with an overall annual growth rate of 5–8%
(IQVIA Institute, 2019). The BRIC (Brazil, Russia, India,
China) nations alone account for roughly 30% of GDP
globally (Mminele, 2016) along with other emerging markets
such as Mexico, Turkey and South Africa (MSCI, 2020).
Opportunities exist for biosimilars in the emerging economies
(Boccia et al., 2017), due to low treatment rates with biologics and
constraints of affordability. However, a strong and clear
regulatory framework is required to unlock the potential of
biosimilars in these markets. Despite the BRICS-TM agencies
basing their guidelines on a common regulatory framework for
Similar Biotherapeutic Products (SBPs) as established by the
WHO (WHO, 2013), the biosimilar regulatory requirements,
structure and processes are still significantly different. It is
therefore challenging to develop biosimilar medicines for
simultaneous submission to all the regulatory authorities (Jain
et al., 2017). Comparisons of the requirements of regulatory
agencies among countries will assist in facilitating
improvements in the integration of regulatory processes. Thus,
agencies from jurisdictions with emerging pharmaceutical markets
might compare themselves with other similarly sized mature
regulatory authorities - regulatory authorities associated with an
ICH member through a legally-binding, mutual recognition
agreement, before October 23, 2015) (WHO, 2021). Also,
comparisons between regulatory authorities of similar size,
regulatory mandates, structures, resource characteristics and
regulatory challenges would be more beneficial than
comparisons between authorities with vastly different
characteristics and competencies (Mashaki Ceyhan et al., 2018).
Studies have been performed to compare the South African
Health Products Regulatory Authority (Keyter et al., 2019),
Turkish Medicines and Medical Devices Agency (Mashaki
Ceyhan et al., 2018), the Saudi Food and Drug Authority
(Hashan et al., 2016) and the Jordan Food and Drug
Administration (Haqaish et al., 2017) with the regulatory
authorities of Australia, Canada, Singapore and Switzerland,
focusing on the area of small molecules.
The aim of this study therefore was to identify, compare and
evaluate the biosimilar regulatory strategy of BRICS-TM agencies
with that of Australia, Canada, Singapore and Switzerland (ACSS
Consortium), in an effort to identify and replicate best practices
in biosimilar development and their authorisation processes.
The objectives of this study were to:
• Identify regulatory framework of the ACSS agencies:
- identify resources of the agencies in the biosimilar domain,
- identify biosimilar development criteria i.e., biosimilarity
principle, comparative studies including physicochemical
characterisation, non-clinical and clinical studies,
- identify the biosimilar marketing authorisation approval
pathway specifically for key milestones, validation time,
queuing time, backlogs, requirement for sample analysis,
conduct of GMP inspections, issuance of Public
Assessment Reports (PARs), scientific guidance
meetings and clinical trial mandates.
• Identify challenges and areas for improvement.
MATERIALS AND METHODS
A semi-quantitative questionnaire was developed for the BRICS-
TM agencies based on an already established questionnaire
developed by the Centre for Innovation in Regulatory Science
(CIRS) (McAuslane et al., 2009) and relevant literature. It was
then decided to name this as the: Biosimilar Development,
Evaluation and Authorisation (BDEA) questionnaire. For the
purpose of this comparison study, it was slightly modified to
reflect organisational differences in the regulatory frameworks of
Australia, Canada, Singapore and Switzerland regulatory
agencies. The rationale for selecting ACSS agencies for the
study is because ACSS agencies are like minded agencies and
promote work sharing for greater regulatory collaboration and
alignment of regulatory requirements. Each of these agencies
leverages each country’s strengths, addresses gaps in science,
knowledge and expertise and resources to expedite risk
assessment, while maintaining or raising quality and safety
standards, thereby allowing for rapid assessments to facilitate
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the market approval of the products (Kühler, 2020). Due to
similarity in regulatory systems between these agencies, the
ACSS consortium was established in 2007 and now renamed
as ACCESS consortium in October 2020 with addition of new
agency of MHRA, United Kingdom (ACSS Consortium updated
to “Access” which includes United Kingdom as on October 2020)
(TGA, 2020). The Consortium builds on international networks,
initiatives and mechanisms to advance work- and information-
sharing throughout the life cycles of health products (WHO,
2020).
The content validity of the BDEA including its relevance was
carried out by amedium sized independent regulatory agency, the
Regulatory Authority of Medicines, Equipment and Medical
Device (CECMED), Cuba. Post validation, the questionnaire
was further concised by removal of duplication of questions
and restructured to make a 35-page long questionnaire. The
BDEA consists of three parts:
Part I - Organisation of the agency - This part of the BDEA
questionnaire consist of current agency structure, resources in
the biosimilar domain and types of regulatory review models
(Type I- Verification review, Type II- Abridged review and
Type III- Full review) employed for scientific assessment, level
of data required, and extent of data assessment of the data
including reliance on other authorities, if applicable. The
rationale for including this section was to assess the
capacity, strengths and weaknesses.
Part II – Agency’s guidelines/views on biosimilar development
criteria - This part includes questions related to biosimilarity
principle, selection of RBP, comprehensive comparability
criteria including physico-chemical, non-clinical and clinical
studies and “must submit” documents that are required for a
biosimilar marketing authorisation application. The rationale
for inclusion of this section was to determine the extent of the
regulatory requirements for biosimilar development and
approval.
Part III – Marketing authorisation approval pathway - This
part covers questions with regards to key milestones i.e, the
assessment process starting from receipt of the dossier,
validation/screening, the number of cycles of scientific
assessments including the questions to the sponsor/
applicant, expert registration committee meetings to the
final decision on approval or rejection of a biosimilar for
registration. A standardised process map, developed based on
the experience of studying established and emerging
regulatory authorities, was embedded in the questionnaire.
The rationale for inclusion of this section was to evaluate
different stages of the review process and timelines for each
milestone.
Eleven regulatory agencies from BRICS-TM and ACSS
countries were invited to take part in this comparative study.
The study protocol was shared with the 11 agencies together with
the electronic self-administered BDEA questionnaire and the
supporting instruction for completion. The data collection
took place between August to November 2020. The potential
study participants were identified via each respective agency’s
general email addresses obtained from agency websites, LinkedIn,
the research team’s personal contacts, ex-employee and local
leading regulatory consultants for each authority. They were
selected based on their work experience in the biologic or
biosimilar division of the authority, having held a position as
a general manager or above (senior management) or a leading
regulatory consultant with a close working relationship with the
relevant authority in the biosimilar domain. They were sent an
electronic mail with brief information about project and the
questionnaire, the objective of the study, the number of
authorities to be included and requesting their agreement to
participate in the study. The questionnaire was completed by a
member of the biologic team and approved by the section head.
This was followed up by a face-to-face or virtual meetings after
receipt of the completed questionnaire with each agency of the
BRICS-TM and ACSS countries. Such meetings were arranged to
verify the validity of the responses to the questionnaire. Also,
copies of the relevant guidelines were requested as part of the
questionnaire to verify the responses and to correlate the actual
regulatory requirements. In addition, data received from the
agency pertaining to number of applications received and
reviewed by agencies in reference (ACSS) and test (BRICS-
TM) group were assessed.
The therapeutics product branch of HSA (Singapore) was
unable to participate due to stretched resources and higher
priorities in other areas due to the COVID-19 pandemic. The
second-best option of approaching leading regulatory consultant
in Singapore was used. However, the participant was unable to
provide the necessary information due to lack of time and
difficulty in obtaining clarity from HSA on certain areas of the
questionnaire.
Data Processing and Analysis
Data processing and analysis were carried out using Microsoft
Excel. The questionnaire (BDEA) is a mixture of qualitative and
quantitative questions. Therefore, both quantitative and
qualitative analyses were carried out. The descriptive statistics
were applied to the quantitative questions of the questionnaire.
The analysis for qualitative data was carried out using content
analysis and inductive coding in order to generate themes and
subthemes (Corbin and Strauss, 1990; Boyatzis, 1998; Thomas,
2006).
Ethics Issues/Statement
The study has been approved by the Health, Science, Engineering
and Technology ECDA, University of Hertfordshire [Reference
Protocol number: aLMS/PGR/UH/03332 (1)].
RESULTS
For the purpose of better clarity, the results will be presented in
three parts:
Part I – Organisation of the agency;
Part II – Biosimilar development criteria; and
Part III – Marketing authorisation process.
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Demographic Status of the Study
Participants
Out of 11 regulatory agencies (i.e., seven BRICS-TM and four
ACSS countries), four BRICS-TM (National Health Surveillance
Agency - ANVISA, Brazil; Central Drug Standards Control
Organisation - CDSCO, India; South African Health Products
Regulatory Agency - SAHPRA; and Turkish Medicines and
Medical Device Agency -TITCK) and three ACSS [Therapeutic
Goods Administration (TGA) Australia, Biologic and
Radiopharmaceutical Drugs Directorate (BRDD) Canada, and
Swissmedic, Switzerland] agencies agreed to participate in the
study. Since access to two agencies, the Federal Commission for
the Protection Against Sanitary Risks (COFEPRIS), Mexico and
the Russian Ministry of Health were experiencing resource
constraints, a leading regulatory consultant, experienced in
working closely with these agencies and having biosimilar
expertise was recruited in each country. The respondents from
the consulting firms were either the Chief Executive Officer or
equivalent. The consultants used for Mexico and Russia were
closely associated with the respective agencies regarding
registration of biosimilar products, engaged with the agencies
for reviewing clinical study protocols and acting as external
assessors for the agency relating to biosimilar products.
National Medical Product Administration (NMPA), China and
Health Science Agency (HSA), Singapore were not able to
complete questionnaire on time, due to lack of resources.
Part I - Organisation of Agency
TGA (Australia) - Though the agency did not have an established
dedicated biologic division, the strength of the assigned biologic
staff was 3.7% of the total. In addition to qualified internal
assessors with B.Sc. to PhD degrees, external evaluators were
engaged for the review of clinical data. Of the three review
models, “Type II- (Abridged)” and “Type III – (Full review)”
of marketing authorisation applications assessments were
frequently carried out by the TGA (Table 1).
BRDD (Canada) - The strength of the biological division within
the agency was 2.08% in comparison with the total staff of the
agency. The agency restricted use of external assessors and had
qualified biological assessors with B.Sc. to PhD degrees. The
marketing authorisation applications were reviewed using “Type
III - Full review”model with little or no scope for relying on “Type I
(Verification)” or “Type II (Abridged review)” models (Table 1).
Instead, the agency reviewed applications through the ACSS
consortium, based on a work-sharing model.
Swissmedic (Switzerland) - There is no distinct biological
division within the agency and hence, with the exception of
CMC reviewers, there were common reviewers for reviewing
both biologic and non-biologic applications. The minimum
qualification of the internal assessors was PhD, PharmD or
MD degree. The agency relied on “Type I (Verification)” and
“Type III (Full review)” models for biosimilar marketing
authorisation applications data assessment.
TABLE 1 | Comparison of organisational structure and review model.
Criteria ANVISA Russia
MoH
CDSCO SAHPRA TITCK COFEPRIS TGA BRDD Swissmedic
Total agency staff 1600 930 1500 > 200 1172 2000 666 > 10,000 435
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aNumber of applications received in 2019-data for 2017 and 2018 not specified by the respondent.
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Comparison of BRICS-TM With ACSS - The strength of
biosimilar assessors across BRICS-TM and ACSS was between
1 and 5%, reflecting no large variance in nine agencies resources.
Most of the BRICS-TM agencies (except ANVISA and Russia
MoH) appointed external assessors to review CMC, non-clinical
and clinical data, as compared to ACSS agencies. The ACSS
agencies followed the “Type III” model for the majority of the
applications and have flexibilities to follow “Type I” (Swissmedic)
and “Type II” (TGA) as well. In addition, these four national
regulatory agencies have formed the ACSS consortium in 2007
with the objective of enhancing the effectiveness and efficiency of
their regulatory systems (TGA, 2020). Some of the BRICS-TM
agencies for example India and Mexico partly aligned with the
ACSS countries regarding review model, but largely resort to
applying Type III (full review) review model. Thus, this indicates
that the BRICS-TM countries should not only strive to achieve
greater reliance on reviews performed by agencies in their
respective region, also to do the same with the established
mature agencies.
Part II - Biosimilar Development Criteria
Biosimilarity
The ACSS agencies expected the sponsor to demonstrate
biosimilarity of the proposed biosimilar product with its
reference product by proving satisfactory physicochemical and
biological characterisation with in vitro non-clinical PK/PD
studies and literature-based clinical performance evaluation,
additional in vivo safety data plus confirmatory clinical safety
and efficacy trials. The TGA, BRDD and Swissmedic accepted
clinical data for the Phase III (clinical efficacy) study from
reference countries and do not mandate applicant to carry out
clinical trials in the local population.
Further, interchangeability is not regulated by law in
Switzerland, allowing the prescriber to decide on switching
based on patients needs. In the case of TGA,
interchangeability policy is under the jurisdiction of the
Department of Health and funded through the Pharmaceutical
Benefits Scheme. The pharmacists of each province in Canada are
charged with the authority to declare two products
interchangeable according to its own rules and regulations,
without the intervention of the prescriber.
The biosimilarity principles of BRICS-TM agencies are aligned
with the expectations of ACSS in terms of different types of
studies. The interchangeability decision in BRICS-TM countries
lies with the prescriber, except in Russia (where it is regulated by
the agency), whereas ACSS follows varied paths. The major
challenge with a few of the BRICS-TM agencies is that they
require the clinical studies to be conducted locally (Rahalkar et al.,
2021), i.e., they do not accept foreign generated clinical data
unlike the ACSS agencies (Table 2).
Comparative Quality Characterisation
Reference Biologic Product (RBP) Selection
The TGA, BRDD and Swissmedic mandated locally authorised
reference products (based on a full dossier including quality,
safety and efficacy) that have been marketed for substantial
periods of time in their country. They also allowed applicants
to use non-locally authorised reference products as part of the
development, in the absence of a locally approved reference
product. The TGA and Swissmedic accepted use or sourcing
of EU or US licensed reference products, whereas BRDD
additionally accepted United Kingdom licensed reference
products. The evidence of bridging studies to prove sameness
of a foreign reference product with the reference product
authorised in respective countries was an essential part of the
submission for applications to TGA and BRDD. While both
agencies required multiple lots of RBP with varied shelf-life for
comparability studies, they did not allow change in the reference
product during development and comparability studies. The
most notable difference was observed with Swissmedic where
the requirement for bridging studies had been removed.
While ACSS agencies are flexible for using non-locally
authorised reference products, ANVISA and Russia MoH
prefer to have locally authorised reference products as part of
the development. Although silence on bridging studies (Rahalkar
et al., 2018) by each of the BRICS-TM agencies, leads to
uncertainty among biosimilar developers, bridging studies
could be an unnecessary burden given that if the reference
product is the same innovator company, any locally approved
product references the same pivotal clinical development data for
approval, with changes in manufacturing sites, for example,
managed through post-approval changes. It could be deduced
that lack of information on bridging studies is in line with good
regulatory practices, unless its omission is in contravention of
international best practice.
Analytical Specification and Method
The TGA, BRDD and Swissmedic followed ICHQ6B (ICH, 1999)
for setting the specification considering manufacturer’s
experience on SBP and RBP.
The BRICS-TM and ACSS agencies were broadly aligned on
this parameter as mentioned in the WHO guidelines (WHO,
2013), except Russia MoH indicating the same specifications for
the proposed biosimilar product as those of the RBP by
discounting the manufacturer’s experience.
Comparative Stability Studies
The TGA recognised the limitations of the biosimilar applicants in
matching the age of the proposed biosimilar products with the
innovator product and hence did not mandate these studies as part
of the application. Swissmedic accepted comparative stability studies
as supportive data while BRDD required it as part of the application.
In general, comparability study expectations of BRICS-TM
regulatory agencies were similar to those required by the ACSS
countries.
Non-clinical Studies
The TGA did not require in vivo toxicity studies if comparability
between the biosimilar and the reference product had been
sufficiently addressed by in vitro studies based on availability
of relevant animal models. Swissmedic followed EMEA/CHMP/
BMWP/42832/2005 Rev1 (EMA, 2014) and product-specific
guidelines, wherein in vivo toxicity studies were required on a
case-by-case basis. The requirements for BRDD were unclear.
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Unlike TGA and Swissmedic, in vivo toxicity study data was
essential requirement for the BRICS-TM agencies.
Clinical Studies
PK/PD
The TGA and Swissmedic both accepted a combined PK/PD
study along with a fingerprinting approach. The design,
endpoints and fingerprinting approach of BRICS-TM agencies
was broadly aligned with ACSS countries.
Immunogenicity
All the ACSS agencies indicated the need for comparative
immunogenicity as part of the biosimilar application. The data could
be obtained from PK/PD studies. The extrapolation of immunogenicity
studies to other indications depends on similarity with the RBP or on
case-to-case basis. Agencies advised applicants to refer to the EMA
immunogenicity guidelines (EMA, 2017) for clarification.
Comparative Clinical Efficacy Studies
Clinical study Design - The TGA, Swissmedic and BRDD
expected randomised, parallel group, double-blind Phase III
clinical trials which are adequately powered using efficacy
endpoints unless there are surrogate markers. Equivalence
design for the comparative clinical efficacy studies is expected
by all the agencies. In addition, TGA also accepted non-inferiority
design for the clinical efficacy trials. The clinical study design
followed by BRICS-TM agencies is mostly aligned with ACSS
countries, with preference over equivalence design. Additionally,
ANVISA, CDSCO and COFEPRIS also accepts non-inferiority
design for clinical studies.
None of the agencies mandate the clinical studies to be
conducted in paediatric or elderly populations for proving
comparability of the proposed biosimilar product.
Local Clinical Studies - The ACSS agencies do not mandate
clinical trials to be conducted locally in their respective countries.
TABLE 2 | Comparison of biosimilar development criteria of BRICS-TM with ACSS agencies.
Criteria BRICS-TM agencies TGA BRDD Swissmedic
Biosimilarity ✓ ✓ ✓ ✓
Physicochemical and biological characterisation with in vitro non-
clinical PK/PD studies and literature-based clinical performance
evaluation, additional in vivo safety data plus confirmatory clinical
safety and efficacy trials
Interchangeability decision by:
Agency Xa Xb X X
Prescriber/physician ✓ X X ✓
Pharmacist X X ✓ X
Comparative quality characterisation
RBP selection
Must be locally authorised ✓ ✓ ✓ ✓
Acceptance of non-locally authorised markets EU, US, Canada, Australia, Japan,
United Kingdom, Germanyc,d,e
EU, US EU, US,
United Kingdom
EU, US
Bridging studies Not specified Required Required Not required
Analytical specification and method ICH Q6B (Except Russia MoH,
specification same as RBP)
ICH Q6B ICH Q6B ICH Q6B
Requirement of comparative stability studies
Mandatory ✓ (ANVISA, Russia MoH, SAHPRA,
COFEPRIS)
X ✓ X
Not mandatory ✓ (CDSCO) ✓ X X
Supportive ✓ (TITCK) X X ✓
Non-clinical studies
In vitro studies ✓ ✓ ✓ ✓
In vivo studies ✓ X (if addressed
in vitro)




Combined PK/PD study, fingerprinting approach ✓ ✓ Not responded ✓
Requirement of immunogenicity studies ✓ (except Russia MoH) ✓ ✓ ✓
Comparative clinical efficacy studies
Clinical study design acceptance ✓ ✓ ✓ ✓
Equivalence design ✓ (ANVISA, CDSCO, COFEPRIS) ✓ X X
Non-inferiority design ✓ (Russia MoH, CDSCO, COFEPRIS) X X X
Local clinical studies
BRICS-TM: ANVISA (Brazil), Russia MoH (Russia), CDSCO (India), NMPA (China), SAHPRA (South Africa), TITCK (Turkey), COFEPRIS (Mexico).
aRegulated by agency in Russia.
bDepartment of Health.
cTITCK.
dCOFEPRIS except United Kingdom, Germany.
eNo recognized reference agencies by Brazil, Russia, South Africa.
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The PK/PD, immunogenicity and clinical efficacy
requirements of BRICS-TM agencies were aligned with ACSS,
however the requirement for local clinical studies were unique to
Russia MoH, CDSCO and COFEPRIS.
Part III - Marketing Authorisation Process
Scientific Advice
The TGA provides pre-submission advice for the biosimilar
application however refrains from providing the same for the
development process. Swissmedic and BRDD offers advice during
the development of the biosimilar via face-to-face meetings,
electronic mail or written responses. The agency advice is not
legally binding.
While ANVISA, CDSCO and SAHPRA were aligned with the
process of scientific advice, Russia MoH, COFEPRIS and TITCK
had yet to develop such communication channels.
Clinical Trial Application (CTA) Approval
Swissmedic reviewed the CTA through internal assessors within
30 days and extended it to 60 days if there was a change in the
manufacturing process of the biosimilar. Flexibility around the
Ethical Committee (EC) letter of submission during evaluation of
the protocol existed with Swissmedic. Prior to initiating a clinical
trial or implementing an amendment to a clinical trial at a site,
BRDD requires the proposed trial protocol and Informed Consent
Form (ICF) to be reviewed and approved by a Research Ethics
Committee (REC) as defined in the regulations. The TGA does not
provide any clarity on the CTA approval process or timelines. Both
ACSS and BRICS-TM countries require an Ethical Committee
letter submitted during clinical trials.
Dossier Review and Approval
The Certificate of Pharmaceutical Product (CPP) in the
technical dossier is not required as part of the application by
ACSS agencies. The validation of the application and target time
to request additional data is in place as one of the milestones.
The current queue time with BRDD is 300 calendar days
whereas such information was unavailable for the TGA and
Swissmedic. External experts for clinical opinion were
contractually engaged by the TGA and Swissmedic. The
deficiencies in the dossier were presented to the applicant in
one single lot from all different sections of the dossier. Sample
analysis was performed as part of the market release post
approval of the product, in Australia and Switzerland. The
GMP inspection is mandated by all the ACSS agencies. For
TGA, the GMP inspection could be either on-site or document-
based verification and the inspection is conducted concurrently
along with the assessment of the product dossier. However,
Swissmedic accepted document-based verification for GMP
certification of the manufacturing site. The BRDD relies on
on-site evaluation for certifying the manufacturer for process
and own inspection or pursuant to MOU’s for GMP purposes
(Table 3). The on-site evaluation is part of the review process
and intends to determine whether a sponsor is “in control” of
their manufacturing processes and has suitable QA processes. It
is a risk-driven process.
The BRICS-TM agencies (except TITCK) were yet to
implement a GMP verification process through off-site review
of documents based on a reference agency approval. TITCK issue
GMP certificate after paper-based evaluation of the GMP
submission.
Public Assessment Report (PAR)
Public assessment reports are issued by TGA, Australia
(AusPAR) and BRDD, Canada for biosimilar products.
Currently, PAR from Swissmedic (SwissPAR) is issued only
for new active substances and is available upon request for
biosimilars. However, among the BRICS-TM countries, only
ANVISA publishes equivalent document on their website.
Publication of PARs by ACSS agencies thus ensures
transparency, by providing access to information by
pharmaceutical industry, other health authorities, healthcare
professionals and patients (Papathanasiou et al., 2016), on the
approved biosimilar product.
A flow chart on the dossier review and approval pathway is
illustrated in Figure 1.
DISCUSSION
Biosimilars offer patients in the emerging economies the
opportunity to receive key biologic therapies that would
otherwise be denied to them due to costs and, therefore, they
offer a great growth potential in such economies. However,
optimal access to biosimilars depends on collaboration
between the relevant stakeholders including policy-makers,
regulators, physicians and the industry. In this context, the
most important role is played by the regulatory authorities as
they provide the regulatory oversight of biosimilars throughout
their product life-cycle to ensure only high-quality, safe and
effective biosimilars are available in the market (WHO, 2017).
However, the regulatory framework for biosimilar development
varies in different jurisdictions (Mintz, 2013). In such cases,
companies are often required to conduct similar but distinct
studies and submit multiple applications for a given product to
agencies in different countries (Institute of Medicine, 2013).
Duplication of such efforts could have negative impacts on
both manufacturers and National Regulatory Authorities
(NRAs) (Ball et al., 2016) and this in turn increases the time
and cost it takes to bring new drugs to market. Aligning the
regulatory strategy across many countries (regulatory
harmonisation) could potentially enhance efficiency (WHO,
2017). This will save time and financial resources for drug
developers, resulting in earlier access for patients to life saving
medicines (Elvidge, 2013).
Comparison of regulatory systems from different countries is
one of the methods to gain insights on the limitations of
regulatory processes, and thereby to overcome some of these
challenges. This study of the guidelines and processes for
biosimilar development and authorisation by regulatory
agencies in BRICS-TM countries in comparison with the
ACSS consortium presents various opportunities to build
efficiencies in their respective regulatory frameworks.
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Although the organisation is contextual and country-specific
often based on country’s legal system, the results for the ACSS
countries showed a great similarity (including biosimilarity
criteria, RBP selection, setting up specification, non-clinical
studies and clinical study requirements). In terms of
regulatory requirements being non-contextual, the results
confirmed this notion by showing a large degree of similarity.
It could be postulated that we could have simply used the
acceptable international best practices for purpose of
comparison, however, given the dynamic nature of biosimilar
development and its expansion, it was envisaged that prospective
up-to-date data collection would provide more accurate head-to-
head comparison.
Effective implementation of a step-wise approach for
demonstration of biosimilarity thereby reducing the need for
studies like in vivo non-clinical studies and repetition of
confirmatory clinical trials in the local population is required
(Rahalkar et al., 2021). A policy paper by IGBA (IGBA, 2020) has
also emphasized the use of strong analytical science and human
pharmacokinetic data for proving quality, safety and efficacy, in-
lieu of confirmatory comparative efficacy clinical trials. This
science-based evaluation and waiving of comparative efficacy
trial has been updated by MHRA, United Kingdom (part of
Access consortium) in its updated guidance on the licensing of
biosimilar product (MHRA, 2021).
Provision of pre-submission advice and scientific advisory
meetings during the biosimilar development and application
process to reduce time and costs. Scientific advice (SA) allows
early communication between the companies and the regulators.
With SA, companies can seek the regulator’s opinion on quality,
nonclinical, and various clinical aspects (e.g., study design, choice
of endpoint, indication) of drug development (Broz et al., 2020;
EMA, 2021). Seeking SA on time can support the development of
safe and efficacious medicines and ensure that the patients get
access to effective treatments in time (EMA, 2021). SA promotes
the efficient use of resources as companies receive feedback on
viable strategies and methodologies for product development.
Companies can plan and design better trials and choose the best
endpoints (Dallmann, 2017). By refining the trial design and
other aspects as per the SA, companies can save valuable time on
prospective queries which may arise during the Clinical Trial
Application (CTA) or Marketing Authorisation Application
(MAA) (Broz et al., 2020). By fostering scientific collaboration,
SA facilitates a working relationship between the company and
the regulatory authority. When incorporated into the drug
development program, SA can add significant value to the
marketing authorisation application. This can significantly
enhance the chances of bringing a medicinal product to
market (Dokumeds, 2021; Alsager et al., 2015). Allowing
applicants to have pre-submission meetings to present the
companies product portfolio and discuss overall filing
strategies are very much welcomed, especially to discuss
products addressing unmet medical need has also been
acknowledged by EFPIA (EFPIA, 2017).
The BRICS-TM agencies might have to consider flexibility for
using non-authorised reference product from other emerging
countries and reference agencies to simplify RBP sourcing. The
sourcing of product batches of different ages from different
markets for development purposes may present significant
difficulties and incur costs (Webster and Woollett, 2017;
Rahalkar et al., 2021). In 2009, the World Health Organisation
(WHO) Expert Committee on Biological Standardization created
a set of recommendations and guidelines to help its member
states implement regulation of biologics and biosimilars.
However, member states still face regulatory challenges, based
on a 2019–2020 WHO survey of participants in 20 countries
(Kang et al., 2021) more specifically related to reference biologics,
including limited access to information on the reference biologic,
financial constraints due to the price of the reference biologic, and
difficulty of obtaining reference biologic samples to assess
comparability. The authors noted some countries accept
reference biologics that are foreign-licensed and -sourced,
whereas others require a domestically licensed reference
product or bridge studies for a foreign-sourced reference
product, which are costly and often result in unnecessary
duplication of studies (Rahalkar et al., 2021). Exchanging
TABLE 3 | Comparison of dossier review and approval process in BRICS-TM with ACSS agencies.
BRICS-TM agencies TGA BRDD Swissmedic
CPP requirement Required Not required Not required Not required
Queue time 28–365 daysa,b No informationb 300 daysa,c No informationa
Support from external experts Yes Yes No information Yes
Sharing of queries on dossier to
sponsor
As they arise during the
assessmentd (or)
Collated into a single batch No information Collated into a single batch
Collated into a single batche
Sample analysis Before approval Part of market release No information Post approval market
surveillancef





BRICS-TM: ANVISA (Brazil), Russia MoH (Russia), CDSCO (India), NMPA (China), SAHPRA (South Africa), TITCK (Turkey), COFEPRIS (Mexico).
aANVISA, MoH Russia, SAHPRA, TITCK, BRDD, Swissmedic follows calendar days.
bCDSCO, COFEPRIS, TGA follows working days.
cTotal review time including submission waiting in queue.
dANVISA, TITCK.
eRussia MoH, CDSCO, SAHPRA, COFEPRIS.
fOn case-by-case basis, possible before approval if any concern regarding quality of the product.
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information with other national regulatory authorities, accepting
foreign-sourced reference products, and avoiding unnecessary
bridge studies were few of the proposed solutions to address these
challenges.
Specifications are critical quality standards that are
proposed and justified by the manufacturer and approved
by the regulatory authorities as conditions of approval (ICH,
1999). It establishes the set of criteria to which a drug substance,
drug product or materials at other stages of its manufacture
should conform to be considered acceptable for its intended
use. They are linked to the manufacturing process and gives
an assurance that the quality is safe and efficacious over
its shelf-life. Most of the BRICS-TM agencies are aligned
with ICH Q6B, except Russia MoH which expects the
specification to of the biosimilar to be same as the reference
biologic product. Hence, aligning with the international
regulatory standards on setting up specifications based on
the manufacturer’s experience with RBP and the proposed
biosimilar product becomes an essential aspect to be
considered by the agency.
TheWorld Health Organisation (WHO) Certification Scheme
was initially implemented to accelerate the availability of new
drugs in developing countries by providing evidence of the
quality of products through the use of the Certificate of
Pharmaceutical Product (CPP) (WHO, 1995; Withing, 2012).
However, combined with increased data requirements and review
FIGURE 1 | Dossier review and approval pathway.
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practices of National Regulatory Authority (NRAs), along with
the requirement to submit CPP at the time of submission, has
delayed the review and approval process and thereby delaying
access to patients (Rodier et al., 2020). Also, in a white paper by
EFPIA (EFPIA, 2017) on reliance and expedited registration
pathways in emerging markets, one of the key points was
avoiding non-essential documentation like the request for CPP
before approval instead of at time of submission, or to waive the
requirement completely. Hence, using alternative data sources
such as agency websites for marketing authorisation confirmation
instead of requiring CPP as part of the submission needs to be
considered by the regulatory agencies of emerging economies like
BRICS-TM.
The BRICS-TM agencies should consider acceptance of off-
site GMP audit in the GMP accreditation process to reduce delays
caused by physical GMP inspections. For instance, the
Pharmaceutical Inspection Co-operation Scheme (PIC/S) (PIC/
S, 2014) aims at facilitating cooperation and networking between
competent authorities, regional and international organisations,
thus increasing mutual confidence regarding inspections.
Reliance is also an important aspect for conducting desktop
assessment of compliance with relevant good practice
guidelines and requirements, as described in the respective
WHO guidance (WHO, 2018). PIC/S has also issued a
guidance on inspection reliance, which outlines a process for
the desk-top assessment of GMP compliance (PIC/S, 2018).
Like the ACSS agencies, the emerging economies of BRICS-
TM need to move towards reliance and collaboration with other
regulatory agencies. A shared or joint review approach for the
assessment of dossier in the marketing authorisation application
with other comparable agencies and a verification review for
products that have been approved by two or more reference
agencies and an abridged review for medicines approved by one
or more agencies, with a full review only employed for those
products that have not been reviewed elsewhere by a reference
agency can be considered for reviewing of the product dossier.
The World Health Organisation (WHO) supports the
implementation of reliance on other regulators work as a
general principle in order to make the best use of available
resources and expertise. This principle enables leveraging the
output of others whenever possible while placing a greater focus
at the national level on value added regulatory activities that
cannot be undertaken by other authorities, such as, but not
limited to, in-country vigilance and market surveillance and
control activities and oversight of local manufacturing and
distribution. Reliance approaches facilitate timely access to
safe, effective and quality-assured medical products and can
help in regulatory preparedness and response, particularly
during public health emergencies (WHO, 2020).
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